Opinion|Videos|November 4, 2024
Future Perspective on Anemia Treatment in LR-MDS
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, explores the future treatment landscape for anemia in lower-risk myelodysplastic syndromes (LR-MDS), discussing the impact of emerging therapies on erythropoietin-stimulating agents (ESAs), identifying unmet needs in anemia management, and sharing clinical insights for community oncologists.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What do you see as the future anemia treatment landscape for LR-MDS? What is the impact of newer therapies on the use of ESAs?
- What are the current unmet needs in the treatment of anemia in LR-MDS?
- What clinical pearls could you share to community oncologists in the treatment of anemia for patients with LR-MDS?
Advertisement
Related to this article
Digital biopsy data show CAN-2409 plus radiation boosts durable lymphocyte-tumor engagement in localized prostate cancer, hinting at stronger immune surveillance and better control.
Adding subcutaneous epcoritamab to R-CHOP significantly improves progression-free survival in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
The ADC rinatabart sesutecan showed efficacy regardless of FRα status in heavily pretreated platinum-resistant ovarian cancer with a tolerable safety profile.
A cisplatin patch achieves 95.5% complete responses in early oral lesions, helping patients avoid surgery with durable control and minimal systemic toxicity.
The RASolute 309 trial is investigating frontline daraxonrasib plus the RAS G12D inhibitor zoldonrasib vs chemotherapy in advanced pancreatic ductal adenocarcinoma.
Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.
Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Behind the FDA Approval of Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
4
PRV111 Shows Strong Responses in Early Oral Cancer
5